Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Discovery

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-17-1256PMID 29650534PMCID PMC5984716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

  2018cited by this paper
• Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer

  2017cited by this paper
• Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

  2017cited by this paper
• First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

  2017cited by this paper
• Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

  2017cited by this paper
• Targeting ALK: Precision Medicine Takes on Drug Resistance.

  2017cited by this paper
• Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

  2017cited by this paper
• Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

  2017cited by this paper
• Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

  2016influential reference
• Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

  2016cited by this paper
• Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

  2016cited by this paper
• Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

  2016influential reference
• Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.

  2016cited by this paper
• First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer.

  2015cited by this paper
• Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

  2015cited by this paper
• PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.

  2015cited by this paper
• Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

  2014cited by this paper
• First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

  2014cited by this paper
• Simulation and estimation of gene number in a biological pathway using almost complete saturation mutagenesis screening of haploid mouse cells

  2014cited by this paper
• The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.

  2014cited by this paper
• Anchored multiplex PCR for targeted next-generation sequencing

  2014cited by this paper
• Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?

  2014cited by this paper
• Patient-derived models of acquired resistance can identify effective drug combinations for cancer

  2014cited by this paper
• Ceritinib in ALK-rearranged non-small-cell lung cancer.

  2014cited by this paper
• P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape

  2014cited by this paper
• Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos

  2014cited by this paper
• Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

  2014cited by this paper
• Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.

  2013cited by this paper
• BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

  2013cited by this paper
• Acquired resistance to crizotinib from a mutation in CD74-ROS1.

  2013cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011influential reference
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Discovery of Candidate Disease Genes in ENU–Induced Mouse Mutants by Large-Scale Sequencing, Including a Splice-Site Mutation in Nucleoredoxin

  2009cited by this paper
• SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

  2008cited by this paper
• Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

  2006cited by this paper
• A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse

  2000cited by this paper

• A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors

  2026cites this paper
• Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer

  2026cites this paper
• Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

  2026cites this paper
• Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China

  2026cites this paper
• Advances in Proteolysis Targeting Chimeras

  2026cites this paper
• Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.

  2026cites this paper
• First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.

  2026cites this paper
• Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report

  2026cites this paper
• Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations

  2025cites this paper
• ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race.

  2025cites this paper
• Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment

  2025cites this paper
• Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis

  2025cites this paper
• MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

  2025cites this paper
• ALK in cancer: from function to therapeutic targeting

  2025cites this paper
• Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer

  2025cites this paper
• Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor

  2025cites this paper
• Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.

  2025cites this paper
• New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer

  2025cites this paper
• Therapeutic potential of lorlatinib in ALK-mutated metastatic paraganglioma: insights from clinical case report and literature review.

  2025cites this paper
• Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

  2025cites this paper
• Discovery of an ALK degrader for lorlatinib-resistant compound mutations.

  2025cites this paper
• Prediction of potential drug-resistant ALK mutations against fourth-generation inhibitors NVL-655 and TPX-0131.

  2025cites this paper
• Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development

  2025cites this paper
• Elucidation of lorlatinib toxicity mechanisms through GC-MS-based metabolomics.

  2025cites this paper
• Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage

  2025cites this paper
• Recent advances in therapeutic strategies for non-small cell lung cancer

  2025cites this paper
• Identifying Genes Associated with the Anticancer Activity of a Fluorinated Chalcone in Triple-Negative Breast Cancer Cells Using Bioinformatics Tools

  2025cites this paper
• [ALK rearrangement in non-small cell lung cancer].

  2025cites this paper
• Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy

  2025cites this paper
• GUK1 activation is a metabolic liability in lung cancer.

  2025cites this paper
• Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical Exposures

  2025cites this paper
• Research Progress on Resistance Mechanisms and Post-Resistance Treatment of Targeted Therapy in Non-Small Cell Lung Cancer

  2025cites this paper
• Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.

  2025cites this paper
• Radiotherapy for large ruptured hemorrhagic axillary lymph node metastasis from anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report and review of literature

  2025cites this paper
• Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.

  2025cites this paper
• Preclinical Prediction of Resistance Mutations and Proposal of Sequential Treatment Strategies for ALK-positive Lung Cancer Using Next-generation ALK Inhibitors

  2025cites this paper
• Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.

  2025cites this paper
• Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC.

  2025cites this paper
• EML4-ALK rearrangement creates a distinctive myeloid cell-dominant immunosuppressive microenvironment in lung cancer.

  2025cites this paper
• Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.

  2025cites this paper
• Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

  2024cites this paper
• Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer

  2024cites this paper
• ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

  2024cites this paper
• Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC

  2024cites this paper
• LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion

  2024influential citation
• Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings

  2024cites this paper
• Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.

  2024cites this paper
• Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC

  2024cites this paper
• New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients

  2024cites this paper
• Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient

  2024cites this paper
• TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer

  2024cites this paper
• Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome.

  2024cites this paper
• Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges

  2024cites this paper
• Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer.

  2024cites this paper
• Current opportunities and challenges in ALK-positive lung cancer

  2024cites this paper
• Salvage pemetrexed for brain metastases from ALK-positive lung cancer after Gamma Knife radiosurgery: illustrative case

  2024cites this paper
• Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis

  2024cites this paper
• ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

  2024cites this paper
• Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

  2024cites this paper
• A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations

  2024cites this paper
• Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments

  2024cites this paper
• Oncogenic alterations in advanced NSCLC: a molecular super-highway

  2024cites this paper
• Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)

  2024cites this paper
• Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer

  2024cites this paper
• Mutant anaplastic lymphoma kinase inhibitor identification by integrated in silico approaches

  2024cites this paper
• Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure

  2024cites this paper
• A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma.

  2024cites this paper
• Cost-effectiveness analysis of lorlatinib and crizotinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer

  2024cites this paper
• Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers.

  2024cites this paper
• NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

  2024influential citation
• In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALKL1196M/G1202R mutation

  2024cites this paper
• Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?

  2024cites this paper
• Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

  2024cites this paper
• Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

  2024cites this paper
• Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory

  2024cites this paper
• Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report

  2024cites this paper
• Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies.

  2024cites this paper
• Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

  2024cites this paper
• Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions

  2024cites this paper
• Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape

  2023cites this paper
• Spectrum of Resistance Mechanisms to ALK TKIs in NSCLC: Largest Single-Center Experience from India

  2023cites this paper
• Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

  2023cites this paper
• Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease

  2023cites this paper
• ALK-positive lung cancer: a moving target

  2023influential citation
• From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

  2023cites this paper
• Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis

  2023cites this paper
• Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N

  2023cites this paper
• Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib

  2023cites this paper
• MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF

  2023cites this paper
• Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer

  2023cites this paper
• FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes

  2023cites this paper
• Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report

  2023cites this paper
• Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure

  2023cites this paper
• Rebiopsie tumorale : quand ? pour qui ? pourquoi ? comment ?

  2023cites this paper
• Oncogenèse pulmonaire et bases biologiques des traitements ciblés

  2023cites this paper
• Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science

  2023cites this paper
• Advances and challenges in the treatment of lung cancer.

  2023cites this paper
• Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC

  2023cites this paper
• Therapy-induced APOBEC3A drives evolution of persistent cancer cells

  2023cites this paper
• Comparison of Experimental and Theoretical spectral groups, electronic properties, topological, and molecular docking investigations of 1-N-Cbz-piperidine-4-carboxylic acid- Potential Cancer drug

  2023cites this paper